Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones

International Journal of Antimicrobial Agents

Volumn 42, Issue 3, 2013, Pages 232-237

  Van Der Heijden, Yuri F ^a,c   Maruri, Fernanda ^a,c   Blackman, Amondrea ^a,c   Mitchel, Ed ^a   Bian, Aihua ^a   Shintani, Ayumi K ^a   Eden, Svetlana ^a   Warkentin, Jon V ^b,c   Sterling, Timothy R ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TENNESSEE DEPARTMENT OF HEALTH   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Ciprofloxacin; Drug resistant tuberculosis; Genotypic resistance; Levofloxacin; Moxifloxacin

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ARTICLE; BACTERIUM ISOLATE; CASE CONTROL STUDY; CODON; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; GENE MUTATION; GYRA GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

CIPROFLOXACIN; DRUG-RESISTANT TUBERCULOSIS; GENOTYPIC RESISTANCE; LEVOFLOXACIN; MOXIFLOXACIN;

ADULT; AGED; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CASE-CONTROL STUDIES; CIPROFLOXACIN; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLINES; TUBERCULOSIS;

EID: 84883449120     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.04.027     Document Type: Article

References (30)

1. D. Falzon, E. Jaramillo, H.J. Schünemann, M. Arentz, M. Bauer, and J. Bayona WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Eur Respir J 38 2011 516 528
2. M.B. Conde, A. Efron, C. Loredo, G.R. De Souza, N.P. Graça, and M.C. Cezar Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial Lancet 373 2009 1183 1189
3. P.D. Gaba, C. Haley, M.R. Griffin, E. Mitchel, J. Warkentin, and E. Holt Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease Arch Intern Med 167 2007 2317 2322
4. R.A. Devasia, A. Blackman, T. Gebretsadik, M. Griffin, A. Shintani, and C. May Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure Am J Respir Crit Care Med 180 2009 365 370
5. R. Long, H. Chong, V. Hoeppner, H. Shanmuganathan, K. Kowalewska-Grochowska, and C. Shandro Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis Clin Infect Dis 48 2009 1354 1360
6. Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999;21:3-40; discussion 41-2.
7. V.T. Andriole The quinolones: past, present, and future Clin Infect Dis 41 Suppl 2 2005 S113 S119
8. J.A. O'Donnell, and S.P. Gelone The newer fluoroquinolones Infect Dis Clin North Am 18 2004 691 716 x
9. Y. Hu, A.R. Coates, and D.A. Mitchison Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis Antimicrob Agents Chemother 47 2003 653 657
10. A.S. Ginsburg, J.H. Grosset, and W.R. Bishai Fluoroquinolones, tuberculosis, and resistance Lancet Infect Dis 3 2003 432 442
11. J. Zhou, Y. Dong, X. Zhao, S. Lee, A. Amin, and S. Ramaswamy Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations J Infect Dis 182 2000 517 525
12. T. Gumbo, A. Louie, M.R. Deziel, and G.L. Drusano Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance Antimicrob Agents Chemother 49 2005 3178 3181
13. T. Gumbo, A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger, and G.L. Drusano Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling J Infect Dis 190 2004 1642 1651
14. F. Maruri, T.R. Sterling, A.W. Kaiga, A. Blackman, Y.F. van der Heijden, and C. Mayer A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system J Antimicrob Chemother 67 2012 819 831
15. F.A. Sirgel, R.M. Warren, E.M. Streicher, T.C. Victor, P.D. van Helden, and E.C. Bottger gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis J Antimicrob Chemother 67 2012 1088 1093
16. C. Xu, B.N. Kreiswirth, S. Sreevatsan, J.M. Musser, and K. Drlica Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis J Infect Dis 174 1996 1127 1130
17. X. Zhao, and K. Drlica Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies Clin Infect Dis 33 Suppl 3 2001 S147 S156
18. K. Drlica, and X. Zhao Mutant selection window hypothesis updated Clin Infect Dis 44 2007 681 688
19. R. Devasia, A. Blackman, S. Eden, H. Li, F. Maruri, and A. Shintani High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility J Clin Microbiol 50 2012 1390 1396
20. R. Devasia, A. Blackman, S. Eden, H. Li, F. Maruri, and A. Shintani Author's correction: High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility J Clin Microbiol 50 2012 2842
21. R.A. Devasia, A. Blackman, C. May, S. Eden, T. Smith, and N. Hooper Fluoroquinolone resistance in Mycobacterium tuberculosis: an assessment of MGIT 960, MODS and nitrate reductase assay and fluoroquinolone cross-resistance J Antimicrob Chemother 63 2009 1173 1178
22. H.E. Takiff, L. Salazar, C. Guerrero, W. Philipp, W.M. Huang, and B. Kreiswirth Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations Antimicrob Agents Chemother 38 1994 773 780
23. S.T. Cole, R. Brosch, J. Parkhill, T. Garnier, C. Churcher, and D. Harris Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence Nature 393 1998 537 544
24. S. Malik, M. Willby, D. Sikes, O.V. Tsodikov, and J.E. Posey New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations PLoS One 7 2012 e39754
25. A.A. Firsov, S.N. Vostrov, I.Y. Lubenko, K. Drlica, Y.A. Portnoy, and S.H. Zinner In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus Antimicrob Agents Chemother 47 2003 1604 1613
26. J. Cui, Y. Liu, R. Wang, W. Tong, K. Drlica, and X. Zhao The mutant selection window in rabbits infected with Staphylococcus aureus J Infect Dis 194 2006 1601 1608
27. K.M. Kam, C.W. Yip, T.L. Cheung, H.S. Tang, O.C. Leung, and M.Y. Chan Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility Microb Drug Resist 12 2006 7 11
28. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. Document M24-A. Wayne, PA: CLSI; 2003.
29. E. Pestova, J.J. Millichap, G.A. Noskin, and L.R. Peterson Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones J Antimicrob Chemother 45 2000 583 590
30. W.W. Yew, C.K. Chan, C.C. Leung, C.H. Chau, C.M. Tam, and P.C. Wong Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong Chest 124 2003 1476 1481